Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Wheeler

Showing results (191-200 of 453) with videos related to

Pageof 46
Sort By:
Arteriosclerosis, Thrombosis, and Vascular Biology|November 16, 2013
Inflammatory stress induces statin resistance by disrupting 3-hydroxy-3-methylglutaryl-CoA reductase feedback regulationYaxi Chen, Halcyon Ku, Lei Zhao, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 15, 2010
Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis populationJürgen Floege, Joseph Kim, Elizabeth Ireland, et al.
Lancet (London, England)|November 6, 2023
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trialHiddo J L Heerspink, Arihiro Kiyosue, David C Wheeler, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|August 14, 2023
Glucose-lowering treatment pathways of individuals with chronic kidney disease and type 2 diabetes according to the Kidney Disease: Improving Global Outcomes 2012 risk classificationCarol Pollock, Juan Jose Garcia Sanchez, Juan-Jesus Carrero, et al.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco|May 31, 2024
Tobacco Exposures are Associated With Healthcare Utilization and Healthcare Costs in Pregnant Persons and Their Newborn BabiesBernard F Fuemmeler, Bassam Dahman, Trevin E Glasgow, et al.
Journal of Medical Economics|October 9, 2023
Translating the efficacy of dapagliflozin in chronic kidney disease to lower healthcare resource utilization and costs: a medical care cost offset analysisPhil McEwan, Marco Hafner, Vivekenand Jha, et al.
Diabetes, Obesity & Metabolism|May 15, 2023
Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trialsVikas S Sridhar, Brendon L Neuen, Robert A Fletcher, et al.
Tobacco Prevention & Cessation|March 17, 2021
An examination of social and environmental determinants of secondhand smoke exposure among non-smoking adolescentsElizabeth K Do, Kennedy C Bradley, Kendall Fugate-Laus, et al.
Kidney International|May 3, 2014
Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global OutcomesMark E Molitch, Amanda I Adler, Allan Flyvbjerg, et al.
Kidney International|November 18, 2017
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammationBenjamin C Storey, Natalie Staplin, Richard Haynes, et al.
Pageof 46

Showing results (191-200 of 453) with videos related to

Sort By:
Pageof 46
Arteriosclerosis, Thrombosis, and Vascular Biology|November 16, 2013
Inflammatory stress induces statin resistance by disrupting 3-hydroxy-3-methylglutaryl-CoA reductase feedback regulationYaxi Chen, Halcyon Ku, Lei Zhao, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 15, 2010
Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis populationJürgen Floege, Joseph Kim, Elizabeth Ireland, et al.
Lancet (London, England)|November 6, 2023
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trialHiddo J L Heerspink, Arihiro Kiyosue, David C Wheeler, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|August 14, 2023
Glucose-lowering treatment pathways of individuals with chronic kidney disease and type 2 diabetes according to the Kidney Disease: Improving Global Outcomes 2012 risk classificationCarol Pollock, Juan Jose Garcia Sanchez, Juan-Jesus Carrero, et al.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco|May 31, 2024
Tobacco Exposures are Associated With Healthcare Utilization and Healthcare Costs in Pregnant Persons and Their Newborn BabiesBernard F Fuemmeler, Bassam Dahman, Trevin E Glasgow, et al.
Journal of Medical Economics|October 9, 2023
Translating the efficacy of dapagliflozin in chronic kidney disease to lower healthcare resource utilization and costs: a medical care cost offset analysisPhil McEwan, Marco Hafner, Vivekenand Jha, et al.
Diabetes, Obesity & Metabolism|May 15, 2023
Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trialsVikas S Sridhar, Brendon L Neuen, Robert A Fletcher, et al.
Tobacco Prevention & Cessation|March 17, 2021
An examination of social and environmental determinants of secondhand smoke exposure among non-smoking adolescentsElizabeth K Do, Kennedy C Bradley, Kendall Fugate-Laus, et al.
Kidney International|May 3, 2014
Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global OutcomesMark E Molitch, Amanda I Adler, Allan Flyvbjerg, et al.
Kidney International|November 18, 2017
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammationBenjamin C Storey, Natalie Staplin, Richard Haynes, et al.
Pageof 46